➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
McKinsey
Medtronic
Mallinckrodt
Johnson and Johnson

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Patent: 7,462,762

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,462,762
Title:Method for producing modified carbon-based metabolism C.sub.4 plants by overexpression of phosphoenolpyruvate carboxylase
Abstract: The invention relates to a method for producing a C.sub.4-type plant having a modified carbon metabolism, comprising the following steps: an expression cassette, which comprises a nucleotide sequence that codes for a phosphoenolpyruvate carboxylase (PEPC), is introduced into at least one cell of plant C.sub.4; the cell thus transformed is cultivated in such a way as to regenerate a C.sub.4 plant containing said expression cassette in the genome thereof.
Inventor(s): Vidal; Jean (Gometz le Chatel, FR), Jeanneau; Matthieu (Saint Valentin, FR), Perez; Pascual (Chanonat, FR), Gerentes; Denise (Le Crest, FR)
Assignee: Biogemma (Paris, FR) Centre National de la Recherche Scientifique (Paris, FR)
Application Number:10/473,966
Patent Claims:see list of patent claims

Details for Patent 7,462,762

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Biogemma (Paris, FR) Centre National de la Recherche Scientifique (Paris, FR) 2021-04-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Biogemma (Paris, FR) Centre National de la Recherche Scientifique (Paris, FR) 2021-04-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Biogemma (Paris, FR) Centre National de la Recherche Scientifique (Paris, FR) 2021-04-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Boehringer Ingelheim
Express Scripts
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.